VivoSeq
Infectious Disease

Clostridioides Difficile Infection

19

Pipeline Programs↗

13

Active Trials↗

11

Companies Involved↗

Clostridioides difficile Infection is an emerging landscape with 19 programs across 11 companies. The most active players are Adiso Therapeutics, AstraZeneca, Acurx Pharmaceuticals Inc.. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

49/100

Pipeline Velocity

22/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Adiso Therapeutics

1 program

Phase 1AstraZeneca logo

AstraZeneca

1 program

Phase 2A

Acurx Pharmaceuticals Inc.

1 program

Phase 2Moderna logo

Moderna

1 program

Phase 2E

Exeliom Biosciences

1 program

Phase 2V

Vedanta Biosciences, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

93%

Small molecule

14 of 15 classified programs — the dominant modality here.

7%ALL OTHERSMonoclonal antibody17%

Small molecule leads; the ring shows all 15 classified programs, each share of the total. Modality classified for 93% of 27 pipeline programs.

Analysis

Trial Status

26

clinical trials

Completed11 · 42%
Recruiting10 · 38%
Not yet recruiting3 · 12%
Approved for marketing1 · 4%
Unknown status1 · 4%

Clinical Trials

Trial Activity

26 trials

VE303 for Prevention of Recurrent Clostridioides Difficile Infection
Recruiting·VVedanta Biosciences, Inc.·Phase 3·NCT06237452·852 enrolled
Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection
Recruiting·RRambam Health Care Campus·N/A·NCT05709184·196 enrolled
Enteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients
Recruiting·RRiverside University Health System Medical Center·Phase 2/3·NCT07221370·176 enrolled
Fecal Microbiota Transplantation Versus Vancomycin or Fidaxomicin in Clostridioides Difficile Infection First Episode or First Recurrence: A Randomized Controlled, Open-label, Multicenter Phase III Clinical Trial
Recruiting·—·Phase 3·NCT05266807·100 enrolled
Diet for Prevention of Recurrent C. Difficile Infection
Recruiting·UUniversity of Michigan·Preclinical·NCT07613645·20 enrolled
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
Recruiting·HHospices Civils de Lyon·Preclinical·NCT06306014·56 enrolled
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of Intestinal Microbiota Transplantation In Patients Undergoing Colon Resection
Recruiting·UUniversity of Minnesota·Phase 1·NCT06370884·40 enrolled
An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection
Recruiting·UUniversity of Minnesota·Phase 1·NCT06692179·40 enrolled
A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides Difficile Infection in Individuals 18 Years of Age and Above
Recruiting·AstraZeneca logoAstraZeneca·Phase 2·NCT07285213·230 enrolled
Secondary Prophylaxis of Recurrent Clostridioides Difficile Infections During Systemic Antibiotics With Vancomycin: A Randomized Controlled Trial
Recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Preclinical·NCT06979609·300 enrolled
Primary Prophylaxis of Clostridioides Difficile Infection With Oral Vancomycin
Not yet recruiting·UUniversity of Maryland, Baltimore·Phase 2/3·NCT07221708·200 enrolled
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection
Not yet recruiting·MMedical University of Warsaw·N/A·NCT07120490·424 enrolled
CMTS0929 for Clostridioides Difficile Infection
Not yet recruiting·TThe Second Hospital of Nanjing Medical University·Phase 1·NCT06836427·12 enrolled
Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection
Completed·UUniversity of Illinois at Chicago·N/A·NCT04317963·180 enrolled
ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
Completed·SSeres Therapeutics, Inc.·Phase 3·NCT03183141·263 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)